Search alternatives:
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
1541
Table 2_Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis.docx
Published 2025“…The subgroup analysis revealed that the efficacy of levetiracetam for preventing early seizures was better than that of phenytion sodium (OR 0.13, 95% CI 0.03–0.56, p = 0.006). …”
-
1542
Image 3_Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis.jpeg
Published 2025“…The subgroup analysis revealed that the efficacy of levetiracetam for preventing early seizures was better than that of phenytion sodium (OR 0.13, 95% CI 0.03–0.56, p = 0.006). …”
-
1543
Image 1_Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis.tif
Published 2025“…The subgroup analysis revealed that the efficacy of levetiracetam for preventing early seizures was better than that of phenytion sodium (OR 0.13, 95% CI 0.03–0.56, p = 0.006). …”
-
1544
Image 2_Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis.tif
Published 2025“…The subgroup analysis revealed that the efficacy of levetiracetam for preventing early seizures was better than that of phenytion sodium (OR 0.13, 95% CI 0.03–0.56, p = 0.006). …”
-
1545
Image 4_Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis.tif
Published 2025“…The subgroup analysis revealed that the efficacy of levetiracetam for preventing early seizures was better than that of phenytion sodium (OR 0.13, 95% CI 0.03–0.56, p = 0.006). …”
-
1546
Replication package for "Measuring trade costs and analyzing the determinants of trade growth between Cambodia and major trading partners: 1993-2019"
Published 2025“…</p><p dir="ltr"><b>Research implications and recommendations: </b>The findings of this study have significant implications for a better understanding of Cambodia's development toward global trade integration over the past two decades. …”
-
1547
Table 1_Optimal fertilizer rate and sowing density can improve oat quality, yield and N and P comprehensive efficiency in the Loess Plateau of China.docx
Published 2025“…By focusing on the sowing density and fertilizer rate, oats can achieve better productivity performance while maximizing nutrients use efficiency. …”
-
1548
Thymoquinone loaded nanoemulgel in streptozotocin induced diabetic wound
Published 2024“…</p> <p>In diabetic wound animal model nanoemulgel showed significant decreased levels of TNF-α, IL-6, MMP-9 and IL-1β. …”
-
1549
Data Sheet 1_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.docx
Published 2025“…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
-
1550
Data Sheet 2_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.csv
Published 2025“…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
-
1551
Table 1_GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.docx
Published 2025“…Finally, no significant change in fasting insulin levels was noticed with an overall SMD of -1.74 (95% CI: [-6.84, 3.37]), which was also not statistically significant (p-value: 0.55). …”
-
1552
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1553
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1554
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1555
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1556
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1557
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1558
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1559
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
1560
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”